CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 131 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2017. The put-call ratio across all filers is 1.26 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $6,000 | -75.0% | 32,600 | -39.0% | 0.01% | -66.7% |
| Q3 2018 | $24,000 | -11.1% | 53,400 | -1.8% | 0.02% | -10.0% |
| Q2 2018 | $27,000 | -78.9% | 54,400 | -1.1% | 0.02% | -80.2% |
| Q1 2018 | $128,000 | -26.0% | 55,000 | -9.8% | 0.10% | -25.2% |
| Q4 2017 | $173,000 | -6.5% | 61,000 | -5.9% | 0.14% | -6.2% |
| Q3 2017 | $185,000 | +15.6% | 64,800 | 0.0% | 0.14% | +14.3% |
| Q2 2017 | $160,000 | -31.6% | 64,800 | 0.0% | 0.13% | -31.9% |
| Q1 2017 | $234,000 | -0.8% | 64,800 | -3.0% | 0.18% | -5.6% |
| Q4 2016 | $236,000 | -12.9% | 66,800 | -0.3% | 0.20% | -4.4% |
| Q3 2016 | $271,000 | -7.8% | 67,000 | 0.0% | 0.20% | -14.6% |
| Q2 2016 | $294,000 | +7.3% | 67,000 | -7.6% | 0.24% | 0.0% |
| Q1 2016 | $274,000 | -13.3% | 72,500 | +259.8% | 0.24% | -10.1% |
| Q4 2015 | $316,000 | – | 20,150 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |